B. Metzler seel. Sohn & Co. AG Takes $1.37 Million Position in Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• B. Metzler seel. Sohn & Co. AG purchased a new stake of 20,695 shares in Arrowhead Pharmaceuticals valued at about $1.37 million, joining other institutions that recently increased positions (institutional ownership ~62.61%).
• Sell-side analysts hold a consensus "Moderate Buy" rating with an average price target of $83.78, and several firms have recently raised targets (e.g., Piper Sandler $110, B. Riley $101, Goldman Sachs $85).
• Arrowhead missed EPS estimates with quarterly earnings of $0.22 but beat revenue expectations at $264.0 million, while insiders sold roughly 33,095 shares (~$2.33 million) over the past three months.

B. Metzler seel. Sohn & Co. AG purchased a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 20,695 shares of the biotechnology company's stock, valued at approximately $1,374,000.

Other institutional investors also recently modified their holdings of the company. M&T Bank Corp lifted its holdings in shares of Arrowhead Pharmaceuticals by 2,569.6% in the fourth quarter. M&T Bank Corp now owns 240,634 shares of the biotechnology company's stock valued at $15,976,000 after purchasing an additional 231,620 shares in the last quarter. Nordea Investment Management AB lifted its holdings in shares of Arrowhead Pharmaceuticals by 74.5% in the third quarter. Nordea Investment Management AB now owns 372,282 shares of the biotechnology company's stock valued at $12,661,000 after purchasing an additional 158,937 shares in the last quarter. HBK Sorce Advisory LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the third quarter valued at about $2,823,000. Erste Asset Management GmbH increased its position in shares of Arrowhead Pharmaceuticals by 55.3% in the third quarter. Erste Asset Management GmbH now owns 73,000 shares of the biotechnology company's stock valued at $2,466,000 after acquiring an additional 26,000 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the third quarter valued at about $287,000. 62.61% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ARWR has been the topic of a number of recent research reports. Piper Sandler reaffirmed an "overweight" rating and issued a $110.00 target price (up from $100.00) on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, January 13th. HC Wainwright reaffirmed a "buy" rating and issued a $100.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, March 25th. Chardan Capital lifted their target price on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a "buy" rating in a research report on Wednesday, January 7th. B. Riley Financial lifted their target price on Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a "buy" rating in a research report on Thursday, January 22nd. Finally, The Goldman Sachs Group lifted their target price on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a "neutral" rating in a research report on Wednesday, January 7th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $83.78.

Arrowhead Pharmaceuticals Price Performance

NASDAQ:ARWR opened at $73.91 on Monday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.38 and a current ratio of 3.38. The stock's 50-day simple moving average is $62.83 and its 200 day simple moving average is $58.51. The company has a market cap of $10.35 billion, a P/E ratio of 48.31 and a beta of 1.26. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $12.44 and a 52-week high of $76.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its quarterly earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share for the quarter, missing analysts' consensus estimates of $0.60 by ($0.38). The business had revenue of $264.03 million for the quarter, compared to analyst estimates of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.Arrowhead Pharmaceuticals's quarterly revenue was up 10461.3% compared to the same quarter last year. During the same period last year, the firm earned ($1.39) EPS. As a group, sell-side analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -3.37 EPS for the current fiscal year.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, CFO Daniel Joseph Apel sold 13,095 shares of the business's stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $71.35, for a total transaction of $934,328.25. Following the transaction, the chief financial officer owned 162,905 shares of the company's stock, valued at $11,623,271.75. The trade was a 7.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James C. Hamilton sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, April 23rd. The stock was sold at an average price of $75.00, for a total value of $750,000.00. Following the transaction, the insider directly owned 226,958 shares in the company, valued at approximately $17,021,850. This trade represents a 4.22% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 33,095 shares of company stock worth $2,326,228. Company insiders own 3.60% of the company's stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.